FDA Clearance Tracker · K964344
IGG ANTI-GLIADIN (IGG-AGA) ANTIBODY TEST KIT
Last checked: Nov 20, 2026Latest source record: May 30, 1997 (this decision)Source: openFDAMethods & limitations
Decided
May 30, 1997
Substantially Equivalent
Time to decision
211 days
Received Oct 31, 1996. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K964344
- Device name
- IGG ANTI-GLIADIN (IGG-AGA) ANTIBODY TEST KIT
- Applicant
- Immco Diagnostics, Inc.
- Applicant location
- Buffalo, NY
- Received
- Oct 31, 1996
- Decided
- May 30, 1997
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Antibodies, Gliadin (MST)
- Device class
- Class II
- Regulation
- 21 CFR 866.5750
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code MST (Antibodies, Gliadin).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K964344
- The applicant filed a statement instead of a public summary, or the summary is not at FDA's usual address. Check the FDA record.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Immco Diagnostics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- ImmuGlo HEp-2 Elite IFA510(k)
K172745 · Decided Jun 5, 2018 · 266 days after receipt
Device type: Antinuclear Antibody, Indirect Immunofluorescent, Antigen, Control (DHN) · Laboratory Medicine & Pathology
K172078 · Decided Mar 30, 2018 · 263 days after receipt
Device type: Autoantibodies, Anti-Ribonucleic Acid Polymerase (Rnap) Iii Antibody (NYO) · Laboratory Medicine & Pathology
K163133 · Decided Aug 8, 2017 · 273 days after receipt
Device type: Antimitochondrial Antibody, Indirect Immunofluorescent, Antigen, Control (DBM) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.